multicentre trial

(redirected from multicentre study)

multicentre trial

A clinical trial conducted using a single protocol, at two or more sites, each with its own clinical investigator.
References in periodicals archive ?
The Phase 1, open-label, multicentre study is intended to evaluate the maximum tolerated dose of AGEN1181 in patients with advanced solid tumours.
In addition, Sosei's AZD4635 is in a Phase 1 open-label, multicentre study as a single agent and in combination with a PD-L1 antibody, durvalumab in solid malignancies; in Phase 1/2a open-label, multicenter, study in combination with oleclumab in previously treated advanced EGFR-driven non-small cell lung cancer (NSCLC); as well as advancing through a Phase 1 clinical programme as a single agent and in combination with anti-PD-L1 antibody durvalumab (IMFINZI) in solid tumours.
The Multicentre Study of Selfharm in England looked at more than 84,000 cases over 12 years and found that a "psychosocial assessment" by specialist staff occurred in 53.2% of them.
The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT), funded by the European Commission, data collect for this cohort terminate in 2003.
With respect to the genetics of MS, a multicentre study of this in the progressive form of MS, presented by F Martinelli (Italy), showed correlation of progression with HLA Class II region, and additionally with markers in several genes including DPD6 and NRG1.
The Women and Infants Transmission Study is a prospective US multicentre study of HIV infection among pregnant women and their infants.
A comparative multicentre study of early and long-term results of different surgical regimens.
A five year multicentre study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamicins, penicillin, clindamycin and metronidazole in the United States.
In conjunction, the company's anaSTILLs study is a randomised, double-blind, multicentre study being conducted in North America studying two dose levels of anakinra, administrated subcutaneously, in comparison to placebo.
The multicentre study was conducted in 251 patients across 76 sites in 14 countries.
The I-SPY 2 TRIAL, sponsored by QuantumLeap Healthcare Collaborative, is a standing phase two randomised, controlled, multicentre study with an adaptive design intended to rapidly screen and identify promising new treatments in specific subgroups of women with newly-diagnosed, locally-advanced breast cancer (Stage II/III).
The phase 2B/3 clinical trial is a double-blind, placebo-controlled, three arm, multicentre study enrolling around 350 patients with Lactose Intolerance symptoms.

Full browser ?